Inventor · disambiguated record
R. Scott Mcivor
Also filed as: MCIVOR R SCOTT
10 granted patents·26 pending applications·167 citations·filing 1996–2023
90Inventor score
Files withUNIV MINNESOTA23IMMUSOFT CORP3DISCOVERY GENOMICS INC2SANGAMO THERAPEUTICS INC2LAOHARAWEE KANUT1
Top patents by PatentIndex Score
36 records- 0198US10166255B2Intracellular genomic transplant and methods of therapyUNIV MINNESOTA·Filed 2016·Granted Jan 1, 2019·43 cites·31 claims
- 0296US9249424B2Intranasal delivery of AAV encoding therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseasesUNIV MINNESOTA·Filed 2013·Granted Feb 2, 2016·79 cites·16 claims
- 0394US11147837B2Modified cells and methods of therapyUNIV MINNESOTA·Filed 2016·Granted Oct 19, 2021·6 cites·49 claims
- 0490US9827295B2Methods to treat mucopolysaccharide type I or deficiency in alpha-L-iduronidase using a recombinant adeno-associated virus encoding alpha-L-iduronidaseUNIV MINNESOTA·Filed 2014·Granted Nov 28, 2017·10 cites·26 claims
- 0588US8609088B2Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseasesWOLF DANIEL A·Filed 2012·Granted Dec 17, 2013·13 cites·17 claims
- 0684US12121567B2Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfataseUNIV MINNESOTA·Filed 2017·Granted Oct 22, 2024·1 cites·25 claims
- 0780US2022125843A1Modified cells and methods of therapyUNIV MINNESOTA·Filed 2021·Application pending·0 cites
- 0878US2023226225A1Adeno-associated virus for therapeutic delivery to central nervous systemUNIV MINNESOTA·Filed 2023·Application pending·0 cites
- 0976US11583556B2Modified cells and methods of therapyUNIV MINNESOTA·Filed 2020·Granted Feb 21, 2023·0 cites·8 claims
- 1076US2021346473A1Adeno-associated virus mediated gene transfer to the central nervous systemUNIV MINNESOTA·Filed 2021·Application pending·0 cites
- 1175US2022211875A1Intranasal administration of adeno-associated virus to treat central nervous system disordersUNIV MINNESOTA·Filed 2022·Application pending·0 cites
- 1275US2021085759A1Methods to treat pompe disease using a recombinant adeno-associated virusUNIV MINNESOTA·Filed 2020·Application pending·0 cites
- 1375US2021085760A1Adeno-associated virus mediated gene transfer to the central nervous systemUNIV MINNESOTA·Filed 2020·Application pending·0 cites
- 1474US7592321B2Methods of treating lysosomal storage related diseases by gene therapyWHITLEY CHESTER B·Filed 2005·Granted Sep 22, 2009·4 cites·10 claims
- 1571US2021369871A1Adeno-associated virus for therapeutic delivery to central nervous systemUNIV MINNESOTA·Filed 2021·Application pending·0 cites
- 1669US2019298812A1Adeno-associated virus mediated gene transfer to the central nervous systemUNIV MINNESOTA·Filed 2019·Application pending·0 cites
- 1768US2023330195A1Methods and compositions for the treatment of neurologic diseaseSANGAMO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1866US2018271955A1Adeno-associated virus mediated gene transfer to the central nervous systemUNIV MINNESOTA·Filed 2018·Application pending·0 cites
- 1966US2018071373A1Adeno-associated virus for therapeutic delivery to central nervous systemUNIV MINNESOTA·Filed 2017·Application pending·0 cites
- 2066US2018271956A1Methods to treat pompe disease using a recombinant adeno-associated virusUNIV MINNESOTA·Filed 2018·Application pending·0 cites
- 2166US2018271957A1Methods to treat ceroid lipofuscinosis using a recombinant adeno-associated virusUNIV MINNESOTA·Filed 2018·Application pending·0 cites
- 2266US2018264090A1Adeno-associated virus mediated gene transfer to the central nervous systemUNIV MINNESOTA·Filed 2018·Application pending·0 cites
- 2365US2022096659A1Method for improving neurological function in mpsi and mpsii and other neurological disordersUNIV MINNESOTA·Filed 2021·Application pending·0 cites
- 2463US2018289839A1Intranasal therapeutic delivery of adeno-associated virus to central nervous systemUNIV MINNESOTA·Filed 2016·Application pending·0 cites
- 2556US11103582B2Method to achieve extended expression of DNA infused into liverIMMUSOFT CORP·Filed 2018·Granted Aug 31, 2021·0 cites·14 claims
- 2656US2020157178A1Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancerMCIVOR R SCOTT·Filed 2019·Application pending·0 cites
- 2753US2024316217A1Methods for preventing cardiac or skeletal defects in diseases including mucopolysaccharidosesUNIV MINNESOTA·Filed 2022·Application pending·0 cites
- 2849US2014141065A1Method to achieve extended expression of dna infused into liverDISCOVERY GENOMICS INC·Filed 2013·Application pending·0 cites
- 2945US2021047619A1B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strengthIMMUSOFT CORP·Filed 2019·Application pending·0 cites
- 3044US2017202931A1Methods and compositions for the treatment of neurologic diseaseSANGAMO THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3144US2019269799A1Method for improving neurological function in mpsi and mpsii and other neurological disordersLAOHARAWEE KANUT·Filed 2017·Application pending·0 cites
- 3243US2022193129A1B cells for in vivo delivery of therapeutic agents and dosages thereofIMMUSOFT CORP·Filed 2018·Application pending·0 cites
- 3343US2002115216A1Composition for delivery of compounds to cellsFiled 2001·Application pending·0 cites
- 3442US6485722B1Method for selective engraftment of drug-resistant hematopoietic stem cellsUNIV MINNESOTA·Filed 1997·Granted Nov 26, 2002·11 cites·34 claims
- 3540US2017233452A1Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancerDISCOVERY GENOMICS INC·Filed 2015·Application pending·0 cites
- 3629US2002081733A1Method to prepare drug-resistant, non-malignant hematopoietic cellsFiled 1996·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when R. Scott Mcivor files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →